0001739614-22-000037.txt : 20220405 0001739614-22-000037.hdr.sgml : 20220405 20220405163211 ACCESSION NUMBER: 0001739614-22-000037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220405 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220405 DATE AS OF CHANGE: 20220405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibrx, Inc. CENTRAL INDEX KEY: 0001739614 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 824257312 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39452 FILM NUMBER: 22807413 BUSINESS ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 795-4220 MAIL ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 8-K 1 inhibrx-20220405.htm 8-K inhibrx-20220405
FALSE000173961400017396142022-04-052022-04-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 5, 2022  
INHIBRX, INC.
(Exact name of registrant as specified in its charter)  
Delaware001-3945282-4257312
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
11025 N. Torrey Pines Road, Suite 200
La Jolla, CA 92037
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (858) 795-4220
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareINBXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



Item 7.01 Regulation FD Disclosure.
On April 5, 2022, Inhibrx, Inc. (the “Company”) issued a press release announcing that it plans to present late-breaking data from its Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (“AATD”) at the American Thoracic Society 2022 Conference to be held May 13-18, 2022 in San Francisco, CA. The full text of the Company's press release regarding this announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 5, 2022
INHIBRX, INC.
By:/s/ Kelly Deck
Name:Kelly Deck
Title:Chief Financial Officer


 EX-99.1 2 ex991inbxtopresentatats.htm EX-99.1 Document
Exhibit 99.1

Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting

SAN DIEGO, April 5, 2022 – Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that late-breaking data from INBRX-101 will be presented at the American Thoracic Society (“ATS”) 2022 Conference to be held May 13th- 18th, 2022 in San Francisco, CA.

Details on the oral presentation are shared below:

Title: INBRX-101: A Novel Recombinant AAT-Fc Fusion Protein That Achieves Normal Serum AAT Levels with Extended Interval Dosing for Patients with Alpha-1 Antitrypsin Deficiency
Session: Late Breaking Mini Symposium. B14. OLD DOGS NEW TRICKS: LATE-BREAKING ABSTRACTS IN OBSTRUCTIVE LUNG DISEASE
Senior Author: Mark Brantly
Date & Time: May 16, 2022, 10:30-10:40 AM PST
Location: Room 3001/3003 (West Building, Level 3), Moscone Center

Details on the poster presentation are shared below:

Title: Evaluation of Safety and Pharmacokinetics of the Recombinant Human AAT-Fc Fusion Protein INBRX-101 in Patients with Alpha-1 Antitrypsin Deficiency
Poster Session: C41. ALPHA-1 ANTITRYPSIN DEFICIENCY
Poster: P393
Lead Speaker: Andrew Veale
Date & Time: May 17, 2022, 11:15 AM - 1:15 PM PST
Location: Area E, Hall F (North Building, Exhibition Level), Moscone Center

Upon release at ATS, the poster and presentation will be accessible through Inhibrx’s website at https://inhibrx.investorroom.com/events-and-presentations.

About AATD and INBRX-101
Alpha-1 Antitrypsin Deficiency (“AATD”) is an under-diagnosed genetic disease affecting an estimated 100,000 patients in the US. It is characterized by insufficient levels of AAT causing emphysema, loss of lung function, and decreased life expectancy. Based on biochemical efficacy, plasma-derived AAT (“pdAAT”) therapy was approved in the 1980s and is administered weekly to maintain serum AAT concentrations above 11 µM, which is below the normal range. Since then, little progress has been made with new treatment modalities and cost/supply of pdAAT remains a challenge.

The INBRX-101 study is an open-label, international Phase 1 trial designed to assess safety, pharmacokinetics (“PK”), pharmacodynamics (“PD”), and immunogenicity (NCT03815396). AATD patients were administered single or multiple doses (three consecutive doses every three weeks) of 10, 40, 80 or 120 mg/kg INBRX-101 via IV infusion.

As of November 2021, 24 AATD patients have been administered INBRX-101 at doses of 10 mg/kg (n=6), 40 mg/kg (n=6), 80 mg/kg (n=6) and 120 mg/kg (n=6). INBRX-101 has been well

Exhibit 99.1
tolerated without serious adverse reactions, dose-limiting toxicities, or severe treatment emergent adverse events. The most common drug related adverse events reported were fatigue (n=5), pruritus (n=5), blood pressure increased (n=5), urticaria (n=4), and infusion related reactions (n=2). Infusion related reactions (e.g., pruritus, blood pressure increased, urticaria, infusion related reactions) were transient, mostly mild (Grade 1 per CTCAEv5.0) except for one moderate event (Grade 2) and responded well to symptomatic therapy.

Serum antigenic PK and functional AAT levels were assessed in 21 AATD patients. Dose-related increases in maximal and total INBRX-101 exposure were observed across the dose range of 10 to 120 mg/kg. A terminal half-life of approximately 15 - 19 days was observed. Preliminary data from multiple doses of 40 mg/kg or 80 mg/kg every three weeks showed accumulation in line with the prolonged half-life. Observed trough levels of functional AAT exceeded those reported historically for pdAAT.

About Inhibrx, Inc.
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with 2seventy bio (formerly bluebird bio), Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

Investor and Media Contact:

Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260

 EX-101.SCH 3 inhibrx-20220405.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 inhibrx-20220405_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 inhibrx-20220405_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
Apr. 05, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 05, 2022
Entity Registrant Name INHIBRX, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39452
Entity Tax Identification Number 82-4257312
Entity Address, Address Line One 11025 N. Torrey Pines Road
Entity Address, Address Line Two Suite 200
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code 858
Local Phone Number 795-4220
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol INBX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001739614
XML 7 inhibrx-20220405_htm.xml IDEA: XBRL DOCUMENT 0001739614 2022-04-05 2022-04-05 false 0001739614 8-K 2022-04-05 2022-04-05 INHIBRX, INC. DE 001-39452 82-4257312 11025 N. Torrey Pines Road Suite 200 La Jolla CA 92037 858 795-4220 false false false false Common Stock, par value $0.0001 per share INBX NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://inhibrx.namespace.com/role/Cover Cover Cover 1 false false All Reports Book All Reports inhibrx-20220405.htm ex991inbxtopresentatats.htm inhibrx-20220405.xsd inhibrx-20220405_lab.xml inhibrx-20220405_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "inhibrx-20220405.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "inhibrx-20220405.htm" ] }, "labelLink": { "local": [ "inhibrx-20220405_lab.xml" ] }, "presentationLink": { "local": [ "inhibrx-20220405_pre.xml" ] }, "schema": { "local": [ "inhibrx-20220405.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "inhibrx", "nsuri": "http://inhibrx.namespace.com/20220405", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "inhibrx-20220405.htm", "contextRef": "i6b3d6d4f9aed42c3a7cd941b3de058c7_D20220405-20220405", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://inhibrx.namespace.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "inhibrx-20220405.htm", "contextRef": "i6b3d6d4f9aed42c3a7cd941b3de058c7_D20220405-20220405", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001739614-22-000037-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001739614-22-000037-xbrl.zip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end